Baird raises price targets for Cencora and Qiagen shares
Baird lifted its Cencora price target to $375 from $373 and Qiagen's to $52 from $50, keeping Qiagen at Outperform, Dow Jones Newswires reports.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Analysts at Baird raised their price target on Cencora shares to $375 from $373. At the same time, the Qiagen target was increased to $52 from $50, and the Outperform rating on Qiagen was kept unchanged.
The details were published by Dow Jones Newswires, citing ratings data from Benzinga.
why it matters
Routine target revisions like these usually reflect a small change in one analyst's valuation. For the broader market the effect is limited, though investors in drug distribution and diagnostics may treat them as one sentiment signal among many.
tags
instruments
sources
- Cencora Price Target Raised to $375.00/Share From $373.00 by Baird — Dow Jones Newswires, 22 October 2026 at 11:32 UTC
- Qiagen Price Target Raised to $52.00/Share From $50.00 by Baird — Dow Jones Newswires, 22 October 2026 at 11:38 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗